Early Multimodal Vasopressors in Septic Shock: When is it Time for Full-Court Press(ors)?

<p>Kyle A. Hess, PharmD (<a href='https://twitter.com/KyleHessPharmD'>@KyleHessPHarmD</a>) describes the rationale for early use of vasopressors with multiple mechanisms of action in patients with septic shock, reviews the literature examining the early initiation of vasopressin in patients with septic shock and identifies patient characteristics associated with positive response to angiotensin II.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>